[1] 黄盛才. PET/CT在鼻咽癌中的应用价值研究进展.广西医学, 2011, 33(2): 224-227.  doi: 10.3969/j.issn.0253-4304.2011.02.037
[2] 何锦添.鼻咽癌66例误诊临床分析.广州医学院学报, 2002, 30(2): 88-89.
[3] Hong RL, Ting LL, Ko JY, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol, 2001, 19(23): 4305-4313.  doi: 10.1200/JCO.2001.19.23.4305
[4] 刘丽娟, 吴金陵, 修新胜, 等. PET/CT显像在鼻咽癌中的应用.中华现代影像学杂志, 2006, 3(5): 398-400.
[5] Liu T, Xu W, Yan WL, et al. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol, 2007, 85(3): 327-335.
[6] King AD, Ma BB, Yan　YY, et　al. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. Br J Radiol, 2008, 81(964): 291-298.  doi: 10.1259/bjr/73751469
[7] 肖勇, 李奕钊, 郭晓君, 等. PET/CT显像在判断鼻咽癌放疗后病灶残留或复发中的价值.广东医学, 2007, 28(7): 1140-1141.  doi: 10.3969/j.issn.1001-9448.2007.07.056
[8] Gordin A, Golz A, Daitzchman　M, et　al. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: diagnostic accuracy and impact on clinical management. Int J Radiat Oncol Biol Phys, 2007, 68(2): 370-376.  doi: 10.1016/j.ijrobp.2006.12.028
[9] 申超, 刘春雨, 姚树展. 18F-FDG PET-CT显像在鼻咽癌治疗后随访中的应用价值.医学影像学杂志, 2007, 17(7): 674-676.  doi: 10.3969/j.issn.1006-9011.2007.07.008
[10] 林映如, 陈应瑞, 李伟雄. FDG-PET判断鼻咽癌放疗后复发的临床价值.实用医学杂志, 2005, 21(20): 2269-2270.  doi: 10.3969/j.issn.1006-5725.2005.20.017
[11] 田月丽, 兰晓莉, 吴志坚, 等. 18F-FDG PET/CT显像在鼻咽癌综合治疗后随访中的诊断及预后评估效能.中国医学影像技术, 2013, 29(3): 349-353.
[12] Chang JT, Chan SC, Yen TC, et al. Nasopharyngeal carcinoma staging by 18F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys, 2005, 62(2): 501-507.
[13] 李天然, 田嘉禾, 赵春雷, 等. 18F-FDG PET/CT评估鼻咽癌远处间隔转移及诊断效能.医学研究杂志, 2008, 27(11): 39-42.  doi: 10.3969/j.issn.1673-548X.2008.11.013
[14] 罗耀武, 马冬, 唐安戊, 等.鼻咽癌放疗后病灶残留或复发18F-FDG PET显像的诊断价值.广东医学, 2005, 26(9): 1228-1230.  doi: 10.3969/j.issn.1001-9448.2005.09.029
[15] Schwartz DL, Ford E, Rajendran J, et al. FDG PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2005, 61(1): 129-136.  doi: 10.1016/j.ijrobp.2004.03.040
[16] Chua DT, Sham JS, Wei WI, et al. The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma. Cancer, 2001, 92(11): 2845-2855.  doi: 10.1002/1097-0142(20011201)92:11<2845::AID-CNCR10133>3.0.CO;2-7
[17] Zheng XK, Chen LH, Wang QS, et al. Influence of[18F] fluorodeoxyglucose positron emission tomography on salvage treatment decision making for locally persistent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 2006, 65(4): 1020-1025.  doi: 10.1016/j.ijrobp.2006.02.037
[18] Krishna SM, James S, Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res, 2006, 115(1): 85-90.
[19] Lee SW, Nam SY, Im KC, et al. Prediction of prognostic using standardized uptake value of 2-18F-fluoro-2-deoxy-d-gluecose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol, 2008, 87(2): 211-216.
[20] Xie P, Yue　JB, Fu Z, et al. Prognostic value of 18F-FDG PET/CT before and after radiotheraphy for locally advanced nasopharyngeal carcinoma. Ann Oncol, 2010, 21(5): 1078-1082.  doi: 10.1093/annonc/mdp430
[21] Xie P, Yue JB, Zhao HX, et al. Prognostic value of 18F-FDG PET /CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol, 2010, 136(6): 883-889.  doi: 10.1007/s00432-009-0729-7
[22] Larson SM, Erdi Y, Akhurst T, et al. Tumour treatment response based on visual and quantitative changes in global tumour glycolysis using PET-FDG imaging. the visual response score and the change in total lesion glycolysis. Clin Positron Imging, 1999, 2(3): 159-171.  doi: 10.1016/S1095-0397(99)00016-3
[23] Chan WK, Mak HK, Huang DW, et al. Nasopharyngeal carcinoma: relationship between 18F-FDG PET-CT maximum standardized uptake value, metabolic tumor volume and total lesion glycolysis and TNM classification. Nucl Med Commun, 2010, 31(3): 206-210.
[24] Yong H, Baum R, Cremerius U, et　al. Measurement of clinical and subclinical tumour response using 18F-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendation. European Organization for Research and Treatment of Cancer(EORTC) PET Study Group. Eur J Cancer, 1999, 35(13): 1773-1782.  doi: 10.1016/S0959-8049(99)00229-4
[25] 王国慧, Lau E W F, Shakher R, 等. 18F-FDG PET/CT显像在鼻咽癌分期及疗效监测中的应用价值.癌症, 2007, 26(6): 638-642.